Acelyrin, Inc. (SLRN) Financial Analysis & Valuation | Quarter Chart
Acelyrin, Inc. (SLRN)
SLRNPrice: $2.27
Fair Value: 🔒
🔒score
Acelyrin, Inc., a clinical biopharma company, focuses on identifying, acquiring, and accelerating the development and commercialization of transformative medicines. The company's lead product candidate is izokibep, a small protein therapeutic designed to inhibit IL-17A with high potency, which ... more
Acelyrin, Inc., a clinical biopharma company, focuses on identifying, acquiring, and accelerating th... more
Description
Shares
| Market Cap | $229.17M | Exchange | NASDAQ |
| Sector | Healthcare | Industry | Biotechnology |
| Country | US | CEO | Mina Kim |
| IPO Date | 2023-05-04 | CAGR | — |
| Employees | 83 | Website | www.acelyrin.com |
| Div. Yield | — | Payout Ratio | — |
| Buy Back Yield | — | Total Yield | — |
SLRN chart loading...
Fundamentals
Technicals
| Enterprise Value | $196.38M | P/E Ratio | -0.84 |
| Forward P/E | — | PEG Ratio | — |
| P/S Ratio | 670.07 | P/B Ratio | 0.56 |
| P/CF Ratio | -0.8 | P/FCF Ratio | -0.8 |
| EPS | $-2.69 | EPS Growth 1Y | — |
| EPS Growth 3Y | — | EPS Growth 5Y | — |
| Revenue Growth 1Y | 106.02% | Gross Margin | -0.15% |
| Operating Margin | -857.72% | Profit Margin | -785.14% |
| ROE | -0.55% | ROA | -0.62% |
| ROCE | -0.71% | Current Ratio | 18.43 |
| Quick Ratio | 18.43 | Cash Ratio | 2.5 |
| Debt/Equity | 0.01 | Interest Coverage | — |
| Altman Z Score | 1.57 | Piotroski Score | 2 |